Zambon Revenue and Competitors
Estimated Revenue & Valuation
- Zambon's estimated annual revenue is currently $596.4M per year.
- Zambon's estimated revenue per employee is $201,000
Employee Data
- Zambon has 2967 Employees.
- Zambon grew their employee count by 9% last year.
Zambon's People
Name | Title | Email/Phone |
---|---|---|
1 | Chief Human Resources & Communications Pharma | Reveal Email/Phone |
2 | COO Breath | Reveal Email/Phone |
3 | CFO | Reveal Email/Phone |
4 | US Country Lead & VP Commercial | Reveal Email/Phone |
5 | Head Inhalation Technology | Reveal Email/Phone |
6 | Head Primary Care Business Unit at Zambon Italia | Reveal Email/Phone |
7 | Head Finance Department | Reveal Email/Phone |
8 | Head Pharmaceutical Development & Industrialization | Reveal Email/Phone |
9 | Head HR | Reveal Email/Phone |
10 | Head Application Competence Center | Reveal Email/Phone |
Zambon Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $13.7M | 31 | -14% | N/A | N/A |
#2 | $7.2M | 36 | 6% | N/A | N/A |
#3 | $17.7M | 88 | 40% | N/A | N/A |
#4 | $28.7M | 143 | 5% | N/A | N/A |
#5 | $1.4M | 7 | N/A | N/A | N/A |
#6 | $15.3M | 76 | 1% | N/A | N/A |
#7 | $596.4M | 2967 | 9% | N/A | N/A |
#8 | $5.4M | 27 | -10% | N/A | N/A |
#9 | $86.8M | 432 | 7% | N/A | N/A |
#10 | $5M | 25 | 4% | N/A | N/A |
What Is Zambon?
Pharmaceutical, Respiratory, Pain, Woman Healthcare and Central Nervous System Zambon is a leading Italian family company that has operated for 109 years in the pharmaceutical and fine-chemical industry. Founded in Vicenza in 1906, today the Group operates directly in 73 countries with 15 operating subsidiaries in Europe, South America and Asia and more than 2,600 employees. Zambon has also facilities in Italy (Vicenza, Lonigo), Switzerland, France, Brazil and China. Zambon primarily operates in three strategic areas: respiratory, pain and women’s health. In these sectors, its business covers the entire value chain. The Group is particularly focusing on strengthening the respiratory area with the treatment of severe diseases such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), with the recent acquisition of Profile Pharma from Philips. Zambon entered also into a new important therapeutic area, the Central Nervous System (CNS), with an innovative molecule for the treatment of Parkinson's disease. CNS and the Respiratory Business are the two main drivers of the company’s development strategy. Zambon is characterised by a strong identity and integrated organisational structure. Zambon Company is the industrial holding company, made up of Zach, Zambon Chemicals, which operates in the production of active ingredients and intermediates in three business areas: generic, custom and Zambon branded products. Other parts of the Group are: Zambon SpA global pharmaceutical business and Z-Cube, the Corporate Venture that supports the validation of drug delivery technologies and medical devices. ZCube has also developed a strong relationship with the International scientific community and has renovated a company history in the research and innovation field thanks to Open Zone, a scientific campus for the exchange of knowledge, research and innovation. In addition Zoé Foundation, was born with the aim of spreading a health’s culture enhancing a good communication both on the academic field and institutional field.
keywords:N/AN/A
Total Funding
2967
Number of Employees
$596.4M
Revenue (est)
9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Zambon News
BOSTON, April 26, 2022 /PRNewswire/ -- Zambon, a multinational pharmaceutical company focused on innovating cure and care to improve...
Zambon, Northesat Pharm, Hunan Huana Pharmaceuticals, Xunda Pharma, FarmaSino Pharmaceutical, Guilin Hwasun.
Zambon Receives U.S. FDA Breakthrough Therapy Designation for CMS I-neb® in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFB).
Zambon, an Italian multinational pharmaceutical company, acquired Breath Therapeutics, a biopharmaceutical company developing an innovative inhalation therapy for Bronchiolitis Obliterans Syndrome (BOS), for € 140m (up to total € 500m subject to regulatory and sales milestones). With the deal, ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $955.6M | 2983 | N/A | N/A |
#2 | $15M | 3093 | 9% | N/A |
#3 | $922M | 3136 | 8% | N/A |
#4 | $822.1M | 3285 | 7% | $738.3M |
#5 | $75M | 3316 | 2% | N/A |